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Abstract
Aim: The purpose of this study was to describe the proportions of patients referred to and attending cardiac rehabili-
tation programmes in Europe and to compare lifestyle and risk factor targets achieved according to participation in a
cardiac rehabilitation programme.
Methods: The EUROASPIRE IV cross-sectional survey was undertaken in 78 centres from 24 European countries.
Consecutive patients aged <80 years with acute coronary syndromes and/or revascularization procedures were inter-
viewed at least six months after their event.
Results: A total of 7998 patients (24% females) were interviewed. Overall, 51% were advised to participate in a cardiac
rehabilitation programme and 81% of them attended at least half of the sessions; being 41% of the study population.
Older patients, women, those at low socio-economic status or enrolled with percutaneous coronary intervention and
unstable angina, as well as those with a previous history of coronary disease, heart failure, hypertension or dysglycaemia
were less likely to be advised to follow a cardiac rehabilitation programme. People smoking prior to the recruiting event
were less likely to participate. The proportions of patients achieving lifestyle targets were higher in the cardiac rehabili-
tation programme group as compared to the non-cardiac rehabilitation programme group: stopping smoking (57% vs
47%, p< 0.0001), recommended physical activity levels (47% vs 38%, p< 0.0001) and body mass index<30 kg/m2 (65% vs
61%, p¼0.0007). However, there were no differences in the blood pressure, lipids and glucose control. Patients who
attended a cardiac rehabilitation programme had significantly lower anxiety and depression scores and better medication
adherence.
Conclusions: Only half of all coronary patients were referred and a minority attended a cardiac rehabilitation pro-
gramme. Those attending were more likely to achieve lifestyle targets, had lower depression and anxiety, and better
medication adherence. There is still considerable potential to further reduce cardiovascular risk by increasing uptake and
fully integrating secondary prevention and cardiac rehabilitation to provide a modern preventive cardiology programme.
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Introduction
The main objectives of cardiac rehabilitation and sec-
ondary cardiovascular disease (CVD) prevention are to
reduce recurrent events and premature disability in
patients with coronary heart disease (CHD) and
increase the chances of longer life expectancy.1
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Cardiac rehabilitation is deﬁned by the World Health
Organisation (WHO, p. 122) as:
The sum of activities required to inﬂuence favourably
the underlying cause of the disease, as well as the best
possible, physical, mental and social conditions, so that
they (people) may, by their own eﬀorts preserve or
resume when lost, as normal a place as possible in the
community. Rehabilitation cannot be regarded as an
isolated form or stage of therapy but must be integrated
within secondary prevention services of which it forms
only one facet.2
Initially, cardiac rehabilitation was recommended in
patients with acute myocardial infarction or cardiac sur-
gery and was focused on supervised exercise programmes.
Subsequently, they gradually evolved into a more com-
prehensive intervention and current practice guidelines
consistently recommend ‘comprehensive rehabilitation’
programmes that should include psychological counsel-
ling, lifestyle interventions in terms of smoking cessation,
healthy eating, weight management, increased physical
activity, as well as blood pressure, lipids and glucose man-
agement to optimise cardiovascular risk reduction and
reduce disability. International guidelines strongly
(Class I) recommend cardiac rehabilitation for all patients
following acute coronary syndrome, revascularisation
procedures, chronic stable angina and heart failure.1,3–5
There is evidence that secondary prevention and cardiac
rehabilitation have a beneﬁcial and cost-eﬀective impact
on all-cause and cardiovascular mortality and the risk of
hospital readmissions.6
However, participation in cardiac rehabilitation and
secondary prevention of CHD in everyday clinical
practice is far from optimal. Implementation of CVD
prevention guidelines in Europe was evaluated by four
cross-sectional surveys, called EUROASPIRE, carried
out in patients following ﬁrst or recurrent clinical diagno-
sis or treatments for CHD starting in 1995. The compari-
son of the most recent three studies over the last 14 years
showed adverse lifestyle trends, a substantial increase in
obesity, central obesity and diabetes, and high prevalence
of persistent smoking, especially in younger patients and
especially women. Blood pressure and low-density lipo-
protein (LDL)-cholesterol targets were reached by only
half and just over one ﬁfth of patients, respectively.7,8
The results of the EUROASPIRE III survey demon-
strated that less than half of the coronary patients
reported receiving advice to follow a cardiac rehabilita-
tion programme (CRP) and only one-third actually
attended some form of cardiac rehabilitation.9
The main objective of this paper is to describe the
determinants of participation and achievement of risk
factor targets in coronary patients in Europe attending
a CRP.
Study population and methods
Sample size and data collection
A detailed description of the study population and
design of EUROASPIRE IV survey has been published
elsewhere.10 In summary, this cross-sectional study was
carried out at 78 hospital centres in 24 European coun-
tries: Belgium, Bosnia and Herzegovina, Bulgaria,
Croatia, Cyprus, Czech Republic, Finland, France,
Germany, Greece, Ireland, Latvia, Lithuania, the
Netherlands, Poland, Romania, Russia, Serbia,
Slovenia, Spain, Sweden, Turkey, Ukraine and the
UK. Patients aged 18 years and <80 years who had
been hospitalised for acute myocardial infarction (AMI;
ICD-10 I21), unstable angina (UA; ICD-10 I20), or
revascularization procedure in the form of elective or
emergency coronary artery surgery (coronary artery
by-pass graft (CABG)) or balloon angioplasty (percu-
taneous coronary intervention (PCI)) were interviewed
and examined at least six months and at most three years
later. Data collectors were trained to use standardised
methods and instruments.
Height and weight were measured in light indoor
clothes without shoes (Seca scales 701 and measuring
stick model 220). Obesity was deﬁned as a body mass
index (BMI)30 kg/m2.
Waist circumference was measured using a metal tape
applied horizontally at the point midway in the mid-
axillary line between the lowest rim of the rib cage and
the tip of the hip bone (superior iliac crest) with the
patient standing. Central obesity was deﬁned as a waist
circumference 88 cm for women and 102 cm for men.
Blood pressure was measured twice on the right
upper arm in a sitting position using an automatic digi-
tal sphygmomanometers (Omron M6) and the mean
was used for all analyses. Raised blood pressure was
deﬁned as blood pressure 140/90mm Hg (140/
80mm Hg in patients with diabetes mellitus).
Breath carbon monoxide was measured in ppm using a
smokelyser (Bedfont Scientiﬁc, Model Microþ). Smoking
at the time of interview was deﬁned as self-reported
smoking, and/or a breath carbon monoxide exceeding
10ppm. Persistent smoking was deﬁned as smoking at
interview among patients reporting themselves to be smo-
kers in the month prior to the index event.
Medication adherence was assessed by the questions
used in the Heart and Soul study.11
Depression and anxiety were assessed using the
Hospital Anxiety and Depression Scale (HADS).
HADS scores <8 were considered as normal.12
Patients were also asked to complete the validated
HeartQoL questionnaire, comprising 14 items. Using
this, global (all items), physical (10 items) and emotional
(four items) scores, calculated as the mean of the item
scores, can be computed with scores ranging between
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zero (lowest Heart Related Quality of Life [HRQL]) and
three (best HRQL).13
Low educational level was deﬁned as completion of
education to primary school level or below.
Venous blood samples were taken for total and high-
density lipoprotein (HDL) cholesterol, triglycerides,
glycated haemoglobin (HbA1c) and LDL cholesterol
(LDL-C) was calculated according to Friedewald’s for-
mula. Elevated LDL-C concentration was deﬁned as
1.8mmol/l. In patients with diabetes, HbA1c was
considered at target if lower than 7%.
The central laboratory was the Disease Risk Unit,
National Institute for Health and Welfare, Helsinki,
Finland, which is accredited by the Finnish Accreditation
Service and fulﬁls the requirements of the standard SFS-
EN ISO/IEC 17025:2005. The laboratory takes part in the
Lipid Standardization Program organised by CDC,
Atlanta, Georgia, USA and external quality assessment
schemes organised by Labquality, Helsinki, Finland.
Data management
Data were submitted online to the data management
centre (EuroObservational Research Program at the
European Heart House, Sophia Antipolis, France) and
were checked for completeness, internal consistency, and
accuracy. All data were stored under the provisions of
the National Data Protection Regulations.
Statistical analyses
Descriptive statistics (means, standard deviation, and
proportions) were used to present information on
patient characteristics. Values of p for the crude com-
parison between the groups were obtained by means of
the Fisher exact test. Calculation of 95% conﬁdence
intervals (CIs) for diﬀerences between proportions was
according to the Agresti-Caﬀo method.14 The impact of
having attended a CRP on reaching lifestyle and risk
factor targets and the use of prophylactic drugs at the
time of the interview (Table 4), expressed as odds ratios
with 95% conﬁdence intervals, was adjusted for age, sex
and educational level according to mixed logistic model-
ling, the latter accounting for the clustering of patients
within centre. A two-sided p< 0.05 was considered as
indicating statistical signiﬁcance. All statistical analyses
were undertaken using SAS statistical software release
9.4 (SAS Institute Inc., Cary, North Carolina, USA).
Ethical procedures
The study complied with the Declaration of Helsinki
and local Ethics Committee approval in all participat-
ing centres. Written, informed consent was obtained
from each participant.
Results
A total of 7998 patients were interviewed on average
1.35 years after their index event (interquartile range
0.95–1.93 years) of whom 7907 (24% females) had
valid information about their participation in a CRP
and were included in the present analysis. The mean age
of patients at the time of interview was 64 years with
67.4% exceeding the age of 60 years. There were wide
variations in the size of the study population between
countries, ranging from 51 patients in Greece to 535
patients in Germany (Supplementary Material
Table 1). The distribution of the recruiting diagnosis
was as follows: CABG 13% (1018), PCI 54% (4272),
AMI 23% (1803) and UA 10% (814).
The proportions of patients who were advised and
attended a CRP by age, gender and recruiting diagnosis
are presented in Table 1. Overall, 51% of patients were
advised to participate in a CRP and 81% of them
attended at least half of the sessions, the latter being
only 41% of the whole study population. By recruiting
diagnosis, the proportion of patients advised to attend
a CRP was highest in the CABG group (65%) and
lowest in the UA group (25%).
The reported advice to participate in a CRP accord-
ing to patients characteristics at discharge is presented
in Table 2. Patients having received advice to attend a
CRP were slightly younger, more often male with a
somewhat higher educational level and had experienced
a previous coronary event less often. These patients
also suﬀered less from comorbidities such as heart fail-
ure, hypertension and dysglycaemia.
Table 3 shows the participation in a CRP, if advised
to do so, according to patients characteristics at dis-
charge. Patients with low educational level and those
smoking in the month prior to recruiting event were less
likely to participate in a CRP if advised. Patient char-
acteristics and risk factor prevalence at interview
according to participation in a CRP is presented in
Table 4. The proportions of patients achieving lifestyle
targets at the time of the interview were higher in the
CRP group as compared to the non-CRP group: smok-
ing cessation (57% vs 47%), recommended physical
activity levels (47% vs 38%) and BMI <30 kg/m2
(65% vs 61%). However, there were no diﬀerences in
the proportions of patients achieving blood pressure,
LDL-cholesterol and HBA1c targets despite the
higher use of blood pressure and lipid-lowering medi-
cation in the CRP group. Furthermore, patients who
attended a CRP had better medication adherence and
lower anxiety and depression scores. With respect to the
HeartQoL instrument, average scores for the global
scale (p< 0.0001) and both physical (p< 0.0001) and
emotional (p¼ 0.03) subscales were signiﬁcantly
higher in patients having followed a CRP, after adjust-
ment for age, gender and educational level. Testing
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CRP-by-sex interaction terms in the models showed
that the impact of attending a CRP programme was
similar for men and women. There were wide variations
in the proportion of patients attending a CRP ranging
from 0% in Greece to Cyprus to 91% in Lithuania
(Supplementary Material Table 1).
The components of the CRPs are shown in Figure 1
and Supplementary Material Table 2. Four-ﬁfths of
patients reported attending supervised exercise pro-
grammes, followed by 74% who had dietary modiﬁca-
tion and weight management and 66% were given
written educational materials. In addition, about
three-ﬁfths of patients reported teaching sessions and
health promotion workshops, and stress modiﬁcation
and relaxation sessions. Strikingly, less than half of
patients who were smokers in the month prior to the
recruiting event attended some form of smoking cessa-
tion sessions.
Discussion
The importance of lifestyle, risk factor and therapeutic
interventions following the development of coronary
disease is strongly evidence-based. The core compo-
nents of a modern preventive cardiology programme,
which unites secondary prevention and cardiac rehabili-
tation, should include comprehensive lifestyle manage-
ment in relation to smoking cessation, healthy diet and
physical exercise, psychosocial support as well as
weight, blood pressure, lipids and glucose management,
and prescription of and adherence to cardioprotective
medications.1,5,15 There is compelling evidence from
systematic reviews and meta-analyses that secondary
prevention and cardiac rehabilitation can reduce mor-
tality, morbidity and hospital re-admissions, and
improve quality of life and psychological well-being in
a cost-eﬀective way.16–22 A 2011 Cochrane systematic
review and meta-analysis of 47 studies that randomised
10,794 CHD patients to exercise-based cardiac rehabili-
tation or usual care, showed that exercise-based cardiac
rehabilitation was associated with a reduction in both
total (risk ratio (RR) 0.87, 95% CI 0.75–0.99) and car-
diovascular mortality (RR 0.74, 95% CI 0.63–0.87)
as well as hospital admissions (RR 0.69, 95% CI
0.51–0.93).17
The contribution of secondary prevention programs
with or without exercise was evaluated in a meta-
analysis of 63 randomised controlled trials including
21,295 patients with CHD.19 Secondary prevention
programmes reduced all-cause mortality (RR 0.85,
95% CI 0.77–0.94). The risk ratio for recurrent myo-
cardial infarction was 0.83 (95% CI 0.74–0.94) over a
median follow-up of 12 months. In 2012, a systematic
review and meta-analysis including 23 trials involving
11,085 randomised patients demonstrated that lifestyle
modiﬁcation programs were associated with reduced
Table 1. Proportion of patients advised and attended a cardiac rehabilitation programme (CRP) by age,
gender and recruiting event.
CRP
Advised % (n)
Attendeda
(among those advised)
% (n)
Attendeda
(among all patients)
% (n)
Age at interview
<50 years 52.6% (355/675) 78.0% (277/355) 41.0% (277/675)
50–59 years 53.2% (1011/1899) 83.1% (840/1011) 44.2% (840/1899)
60–69 years 50.6% (1493/2951) 82.4% (1230/1493) 41.7% (1230/2951)
70 years 48.3% (1150/2382) 79.5% (914/1150) 38.4% (914/2382)
Gender
Men 52.2% (3123/5978) 81.6% (2548/3123) 42.6% (2548/5978)
Women 45.9% (886/1929) 80.5% (713/886) 37.0% (713/1929)
Recruiting event
CABG 77.0% (784/1018) 84.4% (662/784) 65.0% (662/1018)
PCI 44.8% (1913/4272) 81.2% (1553/1913) 36.4% (1553/4272)
AMI 58.0% (1045/1803) 80.9% (845/1045) 46.9% (845/1803)
UA 32.8% (267/814) 75.3% (201/267) 24.7% (201/814)
All 50.7% (4009/7907) 81.3% (3261/4009) 41.2% (3261/7907)
AMI: acute myocardial infarction; CABG: coronary artery by-pass graft; PCI: percutaneous coronary intervention; UA:
unstable angina.
aAt least half of the sessions.
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all-cause and cardiac mortality, and cardiac readmis-
sions and non-fatal reinfarctions.20
By contrast with all previous meta-analyses of car-
diac rehabilitation up to 2011, which consistently
showed reductions in all-cause mortality and cardiovas-
cular mortality, the most recent Cochrane systematic
review on exercise-based cardiac rehabilitation
showed no eﬀect on total mortality, myocardial infarc-
tion or revascularisations.21 This meta-analysis
involved 63 randomised controlled trials (RCTs) with
14,486 participants with myocardial infarction, angina
and coronary revascularisation with a median follow-
up of 12 months and demonstrated a signiﬁcant reduc-
tion in cardiovascular mortality by 26% (RR 0.74, 95%
CI 0.64–0.86) and hospital readmissions by 18% (RR
0.82, 95% CI 0.70–0.96).21 The inclusion of patients
from the controversial UK randomised controlled
trial (Rehabilitation After Myocardial Infarction Trial
(RAMIT)) is one reason for there being no reduction in
all-cause mortality in this meta-analysis.23 In a subse-
quent meta-analysis of contemporary randomised con-
trolled trials published in the period 2010–2015,
including trials of both prevention and rehabilitation
programmes, and also patients with other forms of ath-
erosclerotic CVD, there was also no reduction in all-
cause mortality (RR 1.00, 95% CI 0.88–1.14) but there
were reductions in cardiovascular mortality by 58%
(95% CI 0.21–0.88), myocardial infarction by 30%
Table 2. Reported advice to participate in a cardiac rehabilitation programme (CRP) according to patient’s characteristics at
discharge.
CRP
Difference (95% CI) p-ValueNot advised Advised
Age at recruiting event, mean (SD) 62.9 (9.63) 62.1 (9.53) <0.0001
Female gender 26.8% (1043/3898) 22.1% (886/4009) –4.7% (–6.6% to –2.8%) <0.0001
Low educational level 19.0% (732/3857) 16.2% (649/3994) –2.7% (–4.4% to –1.0%) 0.0015
Recruiting event¼CABG 6.0% (234/3898) 19.6% (784/4009) þ13.6% (þ12.1% to þ15.0%) <0.0001
Recruiting event¼ PCI 60.5% (2359/3898) 47.7% (1913/4009) –12.8% (–15.0% to –10.6%) <0.0001
Recruiting event¼AMI 19.4% (758/3898) 26.1% (1045/4009) þ6.6% (þ4.8% to þ8.5%) <0.0001
Recruiting event¼UA 14.0% (547/3898) 6.7% (267/4009) –7.4% (–8.7% to –6.0%) <0.0001
Previous CABG 7.0% (270/3860) 5.7% (227/3978) –1.3% (–2.4% to –0.2%) 0.020
Previous PCI 21.2% (817/3859) 18.8% (747/3973) –2.4% (–4.1% to –0.6%) 0.0093
Previous AMI 27.9% (1070/3841) 23.7% (936/3957) –4.2% (–6.1% to –2.3%) <0.0001
Previous UA 9.2% (350/3815) 6.5% (256/3940) –2.7% (–3.9% to –1.5%) <0.0001
Previous angina pectoris 29.7% (1139/3834) 24.6% (969/3942) –5.1% (–7.1% to –3.2%) <0.0001
Previous stroke 4.5% (173/3847) 3.8% (152/3973) –0.7% (–1.6% to þ0.2%) 0.14
Previous TIA 2.3% (89/3839) 2.2% (87/3964) –0.1% (–0.8% to þ0.5%) 0.76
Previous PAD 4.5% (173/3835) 4.6% (182/3960) þ0.1% (–0.8% to þ1.0%) 0.87
Previous HF 6.9% (264/3818) 4.9% (195/3954) –2.0% (–3.0% to –0.9%) 0.0002
Smoking in month prior to recruiting event 30.1% (1173/3898) 31.4% (1257/4009) þ1.3% (–0.8% to þ3.3%) 0.23
Obesity at discharge 33.7% (942/2792) 33.8% (913/2699) þ0.1% (–2.4% to þ2.6%) 0.95
Hypertension at discharge 81.0% (2918/3604) 76.1% (2747/3610) –4.9% (–6.8% to –3.0%) <0.0001
Dyslipidaemia at discharge 73.8% (2489/3375) 74.4% (2555/3432) þ0.7% (–1.4% to þ2.8%) 0.52
Abnormal glucose metabolism at discharge 30.5% (1032/3384) 25.7% (873/3396) –4.8% (–6.9% to –2.7%) <0.0001
Medication at discharge
Antiplatelets 97.7% (3761/3851) 98.4% (3899/3962) þ0.8% (þ0.1% to þ1.4%) 0.018
Beta-blockers 85.0% (3263/3840) 87.7% (3456/3940) þ2.7% (þ1.2% to þ4.3%) 0.0005
ACE inhibitors/ARBs 77.3% (2970/3840) 74.8% (2942/3935) –2.6% (–4.5% to –0.7%) 0.0079
Calcium channel blockers 23.5% (902/3842) 14.4% (571/3953) –9.0% (–10.8% to –7.3%) <0.0001
Diuretics 29.9% (1150/3843) 29.5% (1168/3957) –0.4% (–2.4% to þ1.6%) 0.71
Lipid-lowering 90.7% (3475/3830) 90.8% (3563/3925) þ0.1% (–1.2% to þ1.3%) 0.97
Anticoagulants 7.8% (302/3848) 9.4% (370/3957) þ1.5% (þ0.3% to þ2.7%) 0.019
AMI: acute myocardial infarction; ARBs: Angiotensin receptor blockers; CABG: coronary artery by-pass graft; CI: confidence interval; HF: heart failure;
PAD: peripheral artery disease; PCI: percutaneous coronary intervention; SD: standard deviation; TIA: transient ischaemic attack; UA: unstable angina.
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(95% CI 0.54–0.91 and, for the ﬁrst time, stroke by
60% (95% CI 0.22–0.74).22 Importantly, comprehen-
sive prevention and rehabilitation programmes mana-
ging six or more risk factors did signiﬁcantly reduce
all-cause mortality by 37% (RR 0.63, 95% CI 0.43–0.93)
as did programmes taking responsibility for prescrib-
ing, up-titrating and monitoring adherence to cardio-
protective medications (RR 0.35, 95% CI 0.18–0.70.22
These important ﬁndings provide further support for
truly comprehensive prevention and rehabilitation
programmes.
The most recent meta-analysis of 22 RCTs with 4834
participants recruited after the year 2000 addressed the
added value of exercise-based cardiac rehabilitation
against a no-exercise control and found no diﬀerence
in all-cause mortality (19 studies; n¼ 4194; risk diﬀer-
ence 0.00, 95% CI 0.02–0.01, p¼ 0.38) or cardiovas-
cular mortality (nine studies; n¼ 1182; risk
diﬀerence0.01, 95% CI 0.02–0.01, p¼ 0.25).24 This
meta-analysis challenged the eﬀectiveness of exercise-
based cardiac rehabilitation vs no exercise, but the
authors qualiﬁed their conclusion because adherence
to, and ﬁdelity of, the exercise interventions was not
reported and the actual dose of exercise in these trials
could not be quantiﬁed. Therefore the added value of
exercise-based cardiac rehabilitation versus no exercise
Table 3. Participation in a cardiac rehabilitation programme (CRP), if advised to do so, according to patient’s characteristics at
discharge.
CRP
Difference (95% CI) p-ValueNot participated Participateda
Age at recruiting event, mean (SD) 62.3 (9.84) 62.0 (9.46) 0.32
Female gender 23.1% (173/748) 21.9% (713/3261) –1.3% (–4.7% to þ2.0%) 0.46
Low educational level 19.0% (142/746) 15.6% (507/3248) –3.4% (–6.6% to –0.4%) 0.024
Recruiting event¼CABG 16.3% (122/748) 20.3% (662/3261) þ4.0% (þ0.9% to þ6.9%) 0.014
Recruiting event¼ PCI 48.1% (360/748) 47.6% (1553/3261) –0.5% (–4.5% to þ3.5%) 0.81
Recruiting event¼AMI 26.7% (200/748) 25.9% (845/3261) –0.8% (–4.4% to þ2.6%) 0.64
Recruiting event¼UA 8.8% (66/748) 6.2% (201/3261) –2.7% (–5.0% to –0.5%) 0.012
Previous CABG 6.4% (47/732) 5.6% (180/3246) –0.9% (–2.9% to þ1.0%) 0.38
Previous PCI 19.1% (140/733) 18.7% (607/3240) –0.4% (–3.6% to þ2.7%) 0.83
Previous AMI 25.7% (187/728) 23.2% (749/3229) –2.5% (–6.0% to þ1.0%) 0.16
Previous UA 9.0% (65/724) 5.9% (191/3216) –3.0% (–5.4% to –0.9%) 0.0044
Previous angina pectoris 25.9% (188/726) 24.3% (781/3216) –1.6% (–5.2% to þ1.9%) 0.36
Previous stroke 4.1% (30/731) 3.8% (122/3242) –0.3% (–2.0% to þ1.2%) 0.67
Previous TIA 3.4% (25/731) 1.9% (62/3233) –1.5% (–3.0% to –0.2%) 0.017
Previous PAD 5.3% (39/730) 4.4% (143/3230) –0.9% (–2.8% to þ0.8%) 0.28
Previous HF 4.6% (33/726) 5.0% (162/3228) þ0.5% (–1.3% to þ2.1%) 0.64
Smoking in month prior to recruiting event
Obesity at discharge
37.0% (277/748)
35.8% (164/458)
30.0% (980/3261)
33.4% (749/2241)
–7.0% (–10.8% to –3.2%)
–2.4% (–7.2% to þ2.4%)
0.0002
0.33
Hypertension at discharge 79.8% (516/647) 75.3% (2231/2963) –4.5% (–7.9% to –0.9%) 0.017
Dyslipidaemia at discharge 73.8% (425/576) 74.6% (2130/2856) þ0.8% (–3.1% to þ4.8%) 0.71
Abnormal glucose metabolism at discharge 30.0% (180/601) 24.8% (693/2795) –5.2% (–9.2% to –1.2%) 0.010
Medication at discharge
Antiplatelets 99.1% (734/741) 98.3% (3165/3221) –0.8% (–1.6% to þ0.2%) 0.14
Beta-blockers 84.2% (619/735) 88.5% (2837/3205) þ4.3% (þ1.5% to þ7.2%) 0.0018
ACE inhibitors/ARBs 70.1% (515/735) 75.8% (2427/3200) þ5.8% (þ2.2% to þ9.4%) 0.0014
Calcium channel blockers 17.7% (131/740) 13.7% (440/3213) –4.0% (–7.1% to –1.1%) 0.0064
Diuretics 26.4% (195/740) 30.2% (973/3217) þ3.9% (þ0.3% to þ7.4%) 0.040
Lipid-lowering 89.1% (656/736) 91.2% (2907/3189) þ2.0% (–0.4% to þ4.6%) 0.09
Anticoagulants 9.7% (72/739) 9.3% (298/3218) –0.5% (–2.9% to þ1.8%) 0.67
ACE: angiotensin-converting enzyme; AMI: acute myocardial infarction; ARBs: Angiotensin receptor blockers; CABG: coronary artery by-pass graft; CI:
confidence interval; HF: heart failure; PAD: peripheral artery disease; PCI: percutaneous coronary intervention; TIA: transient ischaemic attack;
UA: unstable angina.
aAt least half of sessions.
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remains an open question, but the value of comprehen-
sive prevention and rehabilitation programmes using
cardioproective medications is not in doubt.22
Cardiac rehabilitation continues to be widely under-
used with completely inadequate referral and low par-
ticipation rates. Eﬀective implementation of cardiac
rehabilitation after acute coronary syndrome, coronary
revascularisation, and heart failure has remained sub-
optimal, with overall participation rates <50% over
recent decades despite international recommendations.
Only half of EUROASPIRE IV patients (51%) were
advised to participate in a CRP after their coronary
Table 4. Patient’s characteristics and risk factors prevalence at interview according to participation in a cardiac rehabilitation
programme (CRP).
No CRP, % (n) n¼ 4646 CRP,a % (n) n¼ 3261 Odds ratio (95% CI)b p-Valueb
Stopped smokingc 47.4% (688/1450) 57.4% (563/980) 1.48 (1.25 to 1.74) <0.0001
Physical activity at target 37.8% (1754/4646) 47.3% (1541/3261) 1.45 (1.32 to 1.59) <0.0001
BMI<25kg/m2 17.6% (811/4617) 18.3% (597/3257) 1.05 (0.94 to 1.18) 0.41
BMI<30kg/m2 60.7% (2803/4617) 64.8% (2111/3257) 1.18 (1.07 to 1.29) 0.0007
Blood pressure on targetd 53.9% (2497/4630) 54.5% (1774/3256) 1.00 (0.91 to 1.09) 0.94
LDL cholesterol on targete 19.6% (819/4168) 19.5% (583/2996) 0.99 (0.88 to 1.12) 0.90
HbA1c on targetf 51.1% (643/1259) 54.6% (388/711) 1.15 (0.96 to 1.38) 0.13
Antiplatelets 93.8% (4332/4618) 93.8% (3046/3249) 0.94 (0.78 to 1.14) 0.52
BP-lowering medication 94.7% (4375/4618) 95.8% (3112/3249) 1.27 (1.02 to 1.58) 0.03
Lipid-lowering medication 85.3% (3941/4618) 88.2% (2867/3249) 1.28 (1.12 to 1.46) 0.0004
Medication adherence 93.9% (4342/4626) 95.3% (3102/3256) 1.30 (1.06 to 1.60) 0.01
HADS-Anxiety score< 8 71.2% (3125/4388) 77.2% (2412/3123) 1.35 (1.21 to 1.50) <0.0001
HADS-Depression score< 8 74.4% (3263/4388) 82.3% (2569/3123) 1.56 (1.39 to 1.75) <0.0001
BMI: body mass index; BP: blood pressure; CI: confidence interval; HADS: Hospital Anxiety and Depression Scale; HbA1c: glycated haemoglobin; LDL:
low-density lipoprotein; RA: rheumatoid arthritis.
aAt least half of the sessions; bodds ratio (þ 95% confidence interval) and p-value from logistic model adjusting for age, sex and educational level; cfor
patients smoking in the month prior to the recruiting event; dblood pressure 140/90mm Hg (140/80mm Hg in patients with diabetes); eLDL
cholesterol< 1.8mmol/l; fHbA1c< 7% in patients with diabetes.
Written educational material
Teaching sessions and
health promotion workshops
Smoking cessation*
Dietary modification and
weight management
Supervised exercise programme
Stress modification and relaxation 
Other 3.3%
59.0%
85.0%
73.6%
46.9%
61.7%
65.9%
Figure 1. Components of the cardiac rehabilitation programme (CRP) programme.
*For patients smoking in the month prior to the recruiting event.
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event and four-ﬁfths of them (82%) attended at least
half of the sessions; just over two-ﬁfths (41%) of the
whole study population. Reports from other non-EU
countries show that only about 50% of patients
referred to CR actually enrol and participate in CR.25
Poor participation in a CRP has been attributed to
several factors, including physicians’ reluctance to refer
patients, as well as a lack of cardiac rehabilitation ser-
vices. In EUROASPIRE IV, some patients’ character-
istics at hospital discharge (age, gender, diagnosis and
educational level) were associated with whether advice
was given or not to attend a CRP. Older patients,
women, those with lower educational level or following
PCI and UA, and those with a previous history of cor-
onary disease, heart failure, hypertension or dysglycae-
mia were less likely to be advised to attend a CRP. Even
if advised, smokers and less educated patients were less
likely to participate in a CRP.
Our results are in accordance with previous reviews
and meta-analyses summarising the main predictors of
CRP non-adherence as older age, female, lower educa-
tional and socioeconomic status, lower income/greater
deprivation, having angina and being less physically
active.26,27 A meta-analysis including 241,613 partici-
pants found that women were less likely to be referred
to a CRP compared to men (odds ratio (OR) 0.68, 95%
CI 0.62–0.74).28 A systematic review of 10 published
observational studies including 30,333 coronary
patients found that the determinants of referral to
CRP can be grouped as sociodemographic, medical,
psychological and healthcare system factors.29
Another study of barriers to participation in a CRP
showed that inpatient referral is a very strong predictor
of attendance in a CRP.30 The main characteristics
associated with participation in a CRP were younger
age, male sex, ST elevation myocardial infarction,
revascularization therapy and history of prior myocar-
dial infarction.
In EUROASPIRE IV, patients who reported having
participated in a CRP had signiﬁcantly higher smoking
cessation rates and a larger proportion achieved the
physical activity target. However, even in the CRP
group two-ﬁfths of patients who were smoking at the
time of their recruiting coronary event were still smo-
kers at the time of interview and less than half of
patients were achieving their physical activity target.
In addition, a signiﬁcantly lower proportion of patients
who attended a CRP had symptoms of anxiety and
depression. Although the proportion of patients with
BMI30 kg/m2 was signiﬁcantly lower in the CRP
over a third of patients were still obese. Patients attend-
ing a CRP reported signiﬁcantly better medication
adherence and higher use of blood pressure and lipid-
lowering medication. However, despite the higher
medication use, there were no signiﬁcant diﬀerences in
terms of blood pressure, lipid and glucose control
between the CRP and non-CRP groups. The diﬀerences
in lifestyle at interview between the CRP and non-CRP
groups should be interpreted with caution as they may
be the result of selection bias regarding advice given
and participation with healthier patients more likely
to participate in such programmes.
In EUROASPIRE IV, of those advised to attend a
CRP more than four-ﬁfths of patients reported attend-
ing a supervised exercise programme thus demonstrat-
ing the fundamental problem that lies with the
cardiology profession not giving advice, and with the
underprovision of such programmes in most countries
across Europe. More worryingly, there was no increase
in the proportions of patients being advised, and parti-
cipating in, a CRP between EUROASPIRE III and IV
surveys over a seven-year period. The comparison
between those 18 countries and geographical areas
that participated in both surveys showed that the pro-
portion of patients advised to attend a CRP remained
the same (46% in EUROASPIRE III and 47% in
EUROASPIRE IV, p¼ 0.44) as was the overall partici-
pation in a CRP programme (37% in EUROASPIRE
III and 39% in EUROASPIRE IV, p¼ 0.40). Given the
level of evidence for comprehensive prevention and
rehabilitation programmes it is unacceptable that ser-
vice provision should remain stagnant.
EUROASPIRE IV is a unique database based on
information from medical records and face-to-face
interviews and examinations, using the same protocol
and standardised methods and instruments, including
central laboratory measurements. However, our ﬁnd-
ings must be considered within the context of study
limitations. First, patient populations from participat-
ing countries were identiﬁed from selected geographical
areas; hence caution is required when generalising the
results. Second, patients participating in the study are
more likely to be those who are more interested in their
own health. However, this bias is likely to overestimate
the extent of risk factor control and therefore the
results seen in everyday clinical practice are likely to
be worse. Third, the information about the advice, par-
ticipation and components of the CRP was obtained
from self-reports. In addition, the heterogeneity of
healthcare systems would have a substantial inﬂuence
on the access to and core components of the cardiac
rehabilitation services in each country.
In conclusion, the results of EUROASPIRE IV
show that implementation of cardiac rehabilitation
after acute coronary syndrome and coronary revascu-
larization in Europe has remained stagnant and sub-
optimal with overall participation rates of about 40%
and with wide variations between countries. The main
determinants for non-referral and non-participation in
a CRP were older age, female gender, lower educational
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level, having PCI or UA as the index event, smoking in
the month prior to coronary event and a previous his-
tory of CVD. Although the control of smoking, preva-
lence of obesity and physical activity levels were better,
and the level of anxiety and depression was lower, in
those attending a CPR, there were no diﬀerences in
terms of blood pressure, lipids and glucose manage-
ment. The proportion attending a CRP did not increase
since the previous survey and there were wide vari-
ations in attendance and content of CRPs in Europe.
Therefore there is still considerable potential to fur-
ther reduce the risk of CVD by integrating secondary
prevention and cardiac rehabilitation to provide
modern comprehensive preventive cardiology pro-
grammes addressing all aspects of lifestyle, risk factor
and therapeutic management for all patients with cor-
onary and also other forms of atherosclerotic disease.
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